KALA BIO Phase 2b trial fails; KPI-012 development halted; workforce cut 51%

KALA BIO, Inc.

CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint of complete healing at Week 8; secondary endpoints also failed.
Company ceases development of KPI-012 and MSC-S platform; will explore strategic options and engage with secured lender.
Board approved workforce reduction of ~19 employees (~51%); expected to complete in Q4 2025.
KPI-012 was well-tolerated with no treatment-related serious adverse events observed.

item 2.05item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.